Quantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi-MPS Integration

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 10, 2015, Pages 585-594

  Yu, J ^a   Cilfone, N A ^a   Large, E M ^b   Sarkar, U ^a   Wishnok, J S ^a   Tannenbaum, S R ^a,c   Hughes, D J ^b   Lauffenburger, D A ^a   Griffith, L G ^a   Stokes, C L ^d   Cirit, M ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b Centre for Innovation and Enterprise   (United Kingdom)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Stokes Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HUMAN SERUM ALBUMIN; HYDROCORTISONE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DATA ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; INFLAMMATION; KINETIC PARAMETERS; LIVER; MAXIMUM PLASMA CONCENTRATION; MICROPHYSIOLOGICAL SYSTEM TECHNOLOGY; PHARMACOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; SYSTEMS PHARMACOLOGY; TECHNOLOGY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84945276797     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12010     Document Type: Article

References (40)

1. Arrowsmith, J., A decade of change. Nat. Rev. Drug Discov. 11, 17-18 (2012).
2. Arrowsmith, J., &, Miller, P., Trial watch: Phase II and Phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569-569 (2013).
3. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., &, Rosenthal, J., Clinical development success rates for investigational drugs. Nat. Biotech. 32, 40-51 (2014).
4. Hartung, T., Toxicology for the twenty-first century. Nature 460, 208-212 (2009).
5. Seok, J., et al,. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110, 3507-3512 (2013).
6. Sorger, P.K., et al,. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP workshop group 1-48 (NIH, Bethesda, MD, 2011).
7. Griffith, L.G., &, Swartz, M.A., Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell. Biol. 7, 211-224 (2006).
8. Sweeney, L.M., Shuler, M.L., Babish, J.G., &, Ghanem, A., A cell culture analogue of rodent physiology: Application to naphthalene toxicology. Toxicol. In Vitro 9, 307-316 (1995).
9. Sin, A., Baxter, G.T., &, Shuler, M.L., Animal on a chip: A microscale cell culture analog device for evaluating toxicological and pharmacological profiles. Proc. SPIE 4560, Microfluidics and BioMEMS 98 (2001). doi: 10.1117/12.443045
10. Sin, A., Chin, K.C., Jamil, M.F., Kostov, Y., Rao, G., &, Shuler, M.L., The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol. Prog. 20, 338-345 (2004).
11. Griffith, L.G., &, Naughton, G., Tissue engineering-current challenges and expanding opportunities. Science 295, 1009-1014 (2002).
12. Huh, D., Matthews, B.D., Mammoto, A., Montoya-Zavala, M., Hsin, H.Y., &, Ingber, D.E., Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668 (2010).
13. Domansky, K., Inman, W., Serdy, J., Dash, A., Lim, M.H.M., &, Griffith, L.G., Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10, 51-58 (2010).
14. Yu, J., Peng, S., Luo, D., &, March, J., In vitro 3D human small intestinal villous model for drug permeability determination. Biotechnol. Bioeng. 109, 2173-2178 (2012).
15. Abaci, H.E., Gledhill, K., Guo, Z., Christiano, A.M., &, Shuler, M.L., Pumpless microfluidic platform for drug testing on human skin equivalents. Lab Chip 15, 882-888 (2015).
16. Gunther, A., et al,. A microfluidic platform for probing small artery structure and function. Lab Chip 10, 2341-2349 (2010).
17. Wang, Y., Ahmad, A.A., Sims, C.E., Magness, S.T., &, Allbritton, N.L., In vitro generation of colonic epithelium from primary cells guided by microstructures. Lab Chip 14, 1622-1631 (2014).
18. Lam, M.T., Huang, Y.-C., Birla, R.K., &, Takayama, S., Microfeature guided skeletal muscle tissue engineering for highly organized 3-dimensional free-standing constructs. Biomaterials 30, 1150-1155 (2009).
19. Fabre, K.M., Livingston, C., &, Tagle, D.A., Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue. Exp. Biol. Med. 239, 1073-1077 (2014).
20. Derendorf, H., &, Meibohm, B., Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16, 176-185 (1999).
21. Csajka, C., &, Verotta, D., Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J. Pharmacokinet. Pharmacodyn. 33, 227-279 (2006).
22. Ebrahimkhani, M.R., Neiman, J.A.S., Raredon, M.S.B., Hughes, D.J., &, Griffith, L.G., Bioreactor technologies to support liver function in vitro. Adv. Drug Del. Rev. 69-70, 132-157 (2014).
23. Vivares, A., et al,. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica 45, 29-44 (2015).
24. Clark, A.M., et al,. A microphysiological system model of therapy for liver micrometastases. Exp. Biol. Med. 239, 1170-1179 (2014).
25. Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R., &, Beliles, R.P., Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407-484 (1997).
26. Marino, S., Hogue, I.B., Ray, C.J., &, Kirschner, D.E., A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor. Biol. 254, 178-196 (2008).
27. Gayrard, V., Alvinerie, M., &, Toutain, P.L., Interspecies variations of corticosteroid-binding globulin parameters. Domest. Anim. Endocrinol. 13, 35-45 (1996).
28. Rhen, T., &, Cidlowski, J.A., Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353, 1711-1723 (2005).
29. Slaunwhite, W.R., Lockie, G.N., Back, N., &, Sandberg, A.A., Inactivity in vivo of transcortin-bound cortisol. Science 135, 1062-1063 (1962).
30. Coolens, J.-L., Van Baelen, H., &, Heyns, W., Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J. Steroid Biochem. 26, 197-202 (1987).
31. Dorin, R.I., et al,. Validation of a simple method of estimating plasma free cortisol: role of cortisol binding to albumin. Clin. Biochem. 42, 64-71 (2009).
32. Mendel, C.M., Miller, M.B., Siiteri, P.K., &, Murai, J.T., Rates of dissociation of steroid and thyroid hormones from human serum albumin. J. Steroid Biochem. Mol. Biol. 37, 245-250 (1990).
33. Su, G.L., et al,. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 31, 932-936 (2000).
34. Lu, Y.-C., Yeh, W.-C., &, Ohashi, P.S., LPS/TLR4 signal transduction pathway. Cytokine 42, 145-151 (2008).
35. Su, G.L., Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G256-G265 (2002). doi: 10.1152/ajpgi.00550.2001
36. Lin, W.-W., &, Karin, M., A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175-1183 (2007).
37. Poulin, P., &, Theil, F.-P., Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002).
38. Sung, J.H., Kam, C., &, Shuler, M.L., A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10, 446-455 (2010).
39. Ghanem, A., &, Shuler, M.L., Combining cell culture analogue reactor designs and PBPK models to probe mechanisms of naphthalene toxicity. Biotechnol. Prog. 16, 334-345 (2000).
40. Tatosian, D.A., &, Shuler, M.L., A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol. Bioeng. 103, 187-198 (2009).